Clinical trial • Phase III • Respiratory

Tiotropium bromide for Chronic obstructive pulmonary disease

Phase III trial of Tiotropium bromide for Chronic obstructive pulmonary disease. open-label, none/not specified-controlled. 75 participants.

Overview

Trial Therapeutic Area
Respiratory
Trial Disease
Chronic obstructive pulmonary disease
Trial Stage
Phase III
Drug Modality
Small molecule

Key dates

Initial CTIS Submission Date
27-05-2025
First CTIS Authorization Date
16-09-2025

Trial design

open-label, none/not specified-controlled Phase III trial across 11 sites in Spain.

Open Label
Yes
Comparator
None/Not specified
Target Sample Size
75

Recruitment

Planned Sample Size
75
Recruitment Window Months
3

Geography

Total Number Of Sites
11
Total Number Of Participants
75

Spain

Earliest CTIS Part Ii Submission Date
01-07-2025
Latest Decision Or Authorization Date
16-09-2025
Processing Time Days
77
Number Of Sites
11
Number Of Participants
75

Sites

Site Name
Hospital Universitario Marques De Valdecilla
Department Name
Neumologia
Principal Investigator Name
Carlos Antonio Amado
Principal Investigator Email
carlosantonio.amado@scsalud.es
Contact Person Name
Carlos Antonio Amado
Contact Person Email
carlosantonio.amado@scsalud.es
Site Name
Hospital Universitario La Paz
Department Name
Neumologia
Principal Investigator Name
Juan Fernández Lahera
Principal Investigator Email
jfzlahera@yahoo.es
Contact Person Name
Juan Fernández Lahera
Contact Person Email
jfzlahera@yahoo.es
Site Name
Hospital Universitario Torrecardenas
Department Name
Neumologia
Principal Investigator Name
Belén Navas Bueno
Principal Investigator Email
belnabu@hotmail.com
Contact Person Name
Belén Navas Bueno
Contact Person Email
belnabu@hotmail.com
Site Name
Clinica Sagrada Familia
Department Name
Neumologia
Principal Investigator Name
Arturo Huerta Garcia
Principal Investigator Email
ahuerta@clinicasagradafamilia.com
Contact Person Name
Arturo Huerta Garcia
Site Name
Hospital Universitario Virgen De La Macarena
Department Name
Neumologia
Principal Investigator Name
Agustín Valido Morales
Principal Investigator Email
asvmtino@gmail.com
Contact Person Name
Agustín Valido Morales
Contact Person Email
asvmtino@gmail.com
Site Name
Consorci Mar Parc De Salut De Barcelona
Department Name
Neumologia
Principal Investigator Name
Sergi Pascual Guardia
Principal Investigator Email
spascual@psmar.cat
Contact Person Name
Sergi Pascual Guardia
Contact Person Email
spascual@psmar.cat
Site Name
Hospital Universitario De Salamanca
Department Name
Neumologia
Principal Investigator Name
Jose Ignacio Madruga Martin
Principal Investigator Email
imadruga@saludcastillayleon.es
Contact Person Name
Jose Ignacio Madruga Martin
Contact Person Email
imadruga@saludcastillayleon.es
Site Name
Bellvitge University Hospital
Department Name
Neumologia
Principal Investigator Name
María Salud Santos Pérez
Principal Investigator Email
saludsantos@bellvitgehospital.cat
Contact Person Name
María Salud Santos Pérez
Site Name
Centro de Salud Ensanche de Vallecas
Department Name
Neumologia
Principal Investigator Name
Luis Fernandez Pacheco
Principal Investigator Email
luisfernandezpacheco@gmail.com
Contact Person Name
Luis Fernandez Pacheco
Contact Person Email
luisfernandezpacheco@gmail.com
Site Name
Hospital Universitario Infanta Leonor
Department Name
Neumologia
Principal Investigator Name
Elena Rodríguez Jimeno
Principal Investigator Email
elena.rjimeno@gmail.com
Contact Person Name
Elena Rodríguez Jimeno
Contact Person Email
elena.rjimeno@gmail.com
Site Name
Hospital Universitario Dr Peset Aleixandre
Department Name
Neumologia
Principal Investigator Name
Alberto Herrejon Silvestre
Principal Investigator Email
herrejon_alb@gva.es
Contact Person Name
Alberto Herrejon Silvestre
Contact Person Email
herrejon_alb@gva.es

Sponsor

Primary sponsor

Full Name
Laboratorios Liconsa S.A.
Organisation Type
Pharmaceutical company
Country Of Registered Address
Spain

Investigational products

Investigational Product Name
Tiotropium Bromide Spray 2.5μg, Soft Mist Inhaler device
Active Substance
Tiotropium bromide
Modality
Small molecule
Routes Of Administration
Inhalation (soft mist inhaler)
Route
Inhalation
Starting Dose
2.5μg

Related trials

Other published trials that may interest you.